hotspot -WSS

hotspot

author：knowledge 2025-09-07 21:53:58 - browse：196

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Merck to acquire Harpoon Therapeutics for $680 million

WSS

JPM pitch from hospitals? Revenue streams outside of patient care

Gene therapy denied for Afghan refugee whose father aided U.S.

iTeos Therapeutics debuts first data on TIGIT

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

American taxpayers paid $1.8 trillion in health care costs in 2022

Dark money group runs ads on China biotech bill

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Bright Health sells Medicare Advantage business to Molina

Stigma and the return of syphilis

Medical records are filled with copy

Male doctors called my cancer incurable. A female doctor showed it wasn't

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Childbirth

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Medicare details structure of new drug price negotiation program

Startling documents reveal new facets of Sacklers' opioid empire

explore

Do more moles mean more problems? Not so, says new study

American taxpayers paid $1.8 trillion in health care costs in 2022

Allen Institute goes after foundational questions, CEO Costa says

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Report: NIH

Health insurers say they are turning to AI to cut costs, improve care

Wikipedia

explore

explore

leisure time